Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › The University of North Carolina at Chapel Hill › 18740877
Last updated: April 24, 2026
Application No. 18/740,877

Untitled Application

Unknown
Filed
1600
Examiner
SHIN, DANA H
Art Unit
1635
Tech Center
The University of North Carolina at Chapel Hill
Assignee
The University of North Carolina at Chapel Hill
OA Round
3 (Non-Final)
27%
Grant Probability
At Risk
3-4
OA Rounds
3y 6m
To Grant
55%
With Interview

Interview Optional

— +27.5% interview lift. This examiner has a relatively high allow rate; a written response may suffice.
Based on 1149 resolved cases, 2023–2026

Examiner Intelligence

SHIN, DANA H View full profile →
Grants only 27% of cases
27%
Career Allow Rate
311 granted / 1149 resolved
-32.9% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
86 currently pending
Career history
1235
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
29.3%
-10.7% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
31.3%
-8.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1149 resolved cases

Prosecution Timeline

1600
Application Filed
Nov 07, 2024
Non-Final Rejection
Feb 13, 2025
Response after Non-Final Action
Feb 13, 2025
Response Filed
Mar 11, 2025
Response Filed
Apr 01, 2025
Final Rejection
Jul 02, 2025
Interview Requested
Jul 15, 2025
Examiner Interview Summary
Jul 15, 2025
Applicant Interview (Telephonic)
Jul 30, 2025
Response after Non-Final Action
Jul 30, 2025
Request for Continued Examination
Jul 31, 2025
Response after Non-Final Action
Nov 18, 2025
Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/177,446
Patent 12582723
NOVEL POLYNUCLEOTIDES ENCODING A HUMAN FKRP PROTEIN
2y 5m to grant Granted Mar 24, 2026
15/764,429
Patent 12527834
POLYAMINATED POLYGLUTAMIC ACID-CONTAINING COMPOUNDS AND USES THEREOF FOR DELIVERING OLIGONUCLEOTIDES
2y 5m to grant Granted Jan 20, 2026
16/643,534
Patent 12527883
Retinal Promoter and Uses Thereof
2y 5m to grant Granted Jan 20, 2026
17/481,670
Patent 12529054
U1 snRNP Regulates Gene Expression and Modulates Oncogenicity
2y 5m to grant Granted Jan 20, 2026
17/088,303
Patent 12391946
USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
2y 5m to grant Granted Aug 19, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
27%
Grant Probability
55%
With Interview (+27.5%)
3y 6m
Median Time to Grant
High
PTA Risk
Based on 1149 resolved cases by this examiner. Grant probability derived from career allow rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month